Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 3 , Pages 251-260 , July 2010

Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study

  • Oscar Cuevas

      Affiliations

    • Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
    • ,
  • Emilia Cercenado

      Affiliations

    • Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
    • Corresponding Author InformationCorresponding author. Servicio de Microbiología, Hospital General Universitario Gregorio Marañón, Dr Esquerdo 46, 28007 Madrid, Spain. Tel.: +34-91-586-8459; fax: +34-91-504-4906.
    • ,
  • Mercedes Gimeno

      Affiliations

    • Scientific Department, Tedec-Meiji Farma, Madrid, Spain
    • ,
  • Mercedes Marín

      Affiliations

    • Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
    • ,
  • Pilar Coronel

      Affiliations

    • Scientific Department, Tedec-Meiji Farma, Madrid, Spain
    • ,
  • Emilio Bouza

      Affiliations

    • Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
    • ,
  • Spanish Urinary Tract Infection Study Group (SUTIS)

      Affiliations

    • Members of the SUTIS group are listed in the Acknowledgements.

Received 18 December 2009 ,Accepted 14 February 2010.

References 

  1. Alós JI, Garcia-Pena P, Tamayo J. Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections. Rev. Esp. Quimioter. 2007;20:211–215
  2. Andreu A, Alos JI, Gobernado M, Marco F, de la Rosa M, Garcia-Rodriguez JA. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study. Enferm. Infecc. Microbiol. Clin. 2005;23:4–9
  3. Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn. Microbiol. Infect. Dis. 2009;64:202–212
  4. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19); approved standard. Wayne, PA: CLSI; 2009;
  5. Darkes MJ, Plosker GL. Cefditoren pivoxil. Drugs. 2002;62:319–336(discussion 337–338)
  6. De Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase–producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob. Agents. Chemother. 2006;50:368–370
  7. Díaz MA, Hernández JR, Martínez-Martínez L, Rodríguez-Baño J, Pascual A Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido en hospitales españoles: segundo estudio multicéntrico (proyecto GEIH-BLEE 2006). Enferm. Infecc. Microbiol. Clin. 2009;27:503–510
  8. EUCAST . European Committee on Antimicrobial Susceptibility Testing (EUCAST): expert rules in antimicrobial susceptibility testing, 2008. Available at: http://www.srga.org/eucastwt/MICTAB/index.html2008;
  9. Foster R.T., Sr. (2008) Uncomplicated urinary tract infections in women. Obstet Gynecol Clin North Am 35:235–248, viii.
  10. Gomáriz M, Vicente D, Pérez-Trallero E. Infecciones urinarias no complicadas. Inf. Ter. Sist. Nac. Salud. 1998;22:133–141
  11. Granizo JJ, Gimenez MJ, Barberan J, Coronel P, Gimeno M, Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev. Esp. Quimioter. 2008;21:14–21
  12. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J. Urol. 2005;173:1281–1287
  13. Hernandez M, Garcia J, Munoz J. In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin. Rev. Esp. Quimioter. 2009;22:25–29
  14. Hernandez-Martin J, Roma E, Salavert M, Domenech L, Poveda JL. Cefditoren pivoxil: a new oral cephalosporin for skin, soft tissue and respiratory tract infections. Rev. Esp. Quimioter. 2006;19:231–246
  15. Kahan NR, Chinitz DP, Waitman DA, Dushnitzky D, Kahan E, Shapiro M. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option?. Ann. Pharmacother. 2006;40:2223–2227
  16. Lerma M, Cebrian L, Gimenez M, Coronel P, Gimeno M, Aguilar L, et al. Beta-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes. Rev. Esp. Quimioter. 2008;21:149–152
  17. Lutters M, Vogt N. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst. Rev. 2002;CD001535
  18. Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin. Proc. 2004;79:1048–1053(quiz 1053–1044)
  19. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur. Urol. 2008;54:1164–1175
  20. Sadaba B, Azanza JR, Quetglas EG, Campanero MA, Honorato J, Coronel P, et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev. Esp. Quimioter. 2007;20:51–60
  21. Sevillano D, Aguilar L, Alou L, Gimenez MJ, Torrico M, Gonzalez N, et al. Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren–pivoxil. Antimicrob. Agents Chemother. 2008;52:1184–1186
  22. Tenover FC, Emery SL, Spiegel CA, Bradford PA, Eells S, Endimiani A, et al. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results.. J. Clin. Microbiol. 2009;47:294–299
  23. Wagenlehner FM, Weidner W, Naber KG. An update on uncomplicated urinary tract infections in women. Curr. Opin. Urol. 2009;19:368–374

PII: S0732-8893(10)00049-0

doi: 10.1016/j.diagmicrobio.2010.02.013

Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 3 , Pages 251-260 , July 2010

Article Tools

* Image Usage & Resolution